Bristol Myers Squibb at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Bristol Myers Squibb brings 2 presentations to ENA 2026 in Barcelona. Its program covers protein degradation and the molecular subtypes of colorectal cancer. The headline is BMS-986500, a molecular glue degrader of Cyclin E1 aimed at CCNE1-amplified cancers and at CDK4/6 inhibitor resistance in HR+ breast cancer.
| Organization | ENA 2026 Attendance |
|---|---|
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with oncology medicines in immunotherapy, cell therapy and protein degradation. | Talk Fri Nov 20 3:45–3:55pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from Bristol Myers Squibb
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction